Tectonic Therapeutic, Inc. (TECX)
Nasdaq: TECX · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2016
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Feb 26, 2026 | Mar 20, 2025 | Mar 14, 2024 | Mar 23, 2023 | Mar 17, 2022 | Mar 18, 2021 | Mar 16, 2020 | Mar 25, 2019 | · | · |
| Research and development | 63,489 | 41,364 | 36,966r | 72,186 | 83,114 | 87,236 | 54,974 | 35,095 | 15,191 | · |
| General and administrative | 20,547 | 16,651 | 7,682r | 33,248 | 35,727 | 32,992 | 20,835 | 11,148 | 3,195 | · |
| Total operating expenses | 84,036 | 58,015 | 44,648r | 105,434 | 118,841 | 120,228 | 75,809 | 46,243 | 18,386 | · |
| Total costs and expenses | 3,715 | 3,619 | 3,578r | 2,971 | · | · | · | · | · | · |
| Operating income | -84,036 | -58,015 | -44,648r | -105,434 | -118,841 | -120,228 | -75,809 | -46,243 | -18,386 | · |
| Interest expense | 63 | 107 | 152 | 1,808 | 203 | · | · | · | · | · |
| Interest and investment income | 11,297 | 4,261 | 581 | -299 | -224 | 719 | 2,934 | 1,726 | 57 | · |
| Other income (expense), net | -119 | -511 | 396 | · | · | · | · | · | · | · |
| Total non-operating income (expense) | 11,115 | 33 | 1,825r | -456 | -285 | 516 | 2,844 | -118 | -262 | · |
| Income before income taxes | -72,921 | -57,982 | · | · | · | · | · | · | · | · |
| Income tax expense | 1,230 | 0 | 0r | 0 | · | · | · | · | · | · |
| Net income including non-controlling interests | -74,151 | -57,982 | -42,823r | -105,890 | -119,126 | -119,712 | -72,965 | -46,361 | -18,648 | · |
| Net income | -74,151 | -57,982 | -42,823r | -105,890 | -119,126 | -119,712 | -72,965 | -46,361 | -18,648 | · |
| Net income to common shareholders | -74,151 | -57,982 | -42,823r | -105,890 | · | · | · | · | · | · |
| Earnings per share, basic | -4.05 | -6.83 | -33.76r | -2.42 | -2.78 | · | · | · | · | · |
| Earnings per share, diluted | -4.05 | -6.83 | -33.76r | -2.42 | -2.78 | · | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -2.78 | -3.31 | -2.66 | -3.62 | -8.38 | · |
| Weighted average shares, basic | 18,322,533 | 8,490,171 | 1,268,512r | 43,739,000r | 42,854 | · | · | · | · | · |
| Weighted average shares, diluted | 18,322,533 | 8,490,171 | 1,268,512r | 43,739,000r | 42,854,000b | · | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 42,854,000 | 36,206,000 | 27,432,000r | 13,435,478 | 2,235,865 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:CostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseDebtInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterest
us-gaap:InvestmentIncomeNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted